Goncalves Fernanda de Toledo, Firigato Isabela, Pessotto Anne Victorio, Carvalho Soares Felipe Henrique, Martins Fernanda, Dos Santos Rosa Talita, Kubota Gabriel Taricani, de Andrade Daniel Ciampi, Faria Viviane G, Fregni Felipe, Battistella Linamara Rizzo, Imamura Marta, MIziara Ivan Dieb
LIM40-Departamento de Medicina Legal, Bioetica, Medicina do Trabalho e Medicina Fisica e Reabilitacao da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.
Centro de dor do Ambulatorio da Neurologia do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.
Pain Rep. 2025 Jun 18;10(4):e1287. doi: 10.1097/PR9.0000000000001287. eCollection 2025 Aug.
SARS-CoV-2 infection has been linked with chronic pain, leading to disability and affecting quality of life. Single nucleotide polymorphisms in the Mu-opioid receptor gene, which influence pain intensity, perception, and analgesic response, may contribute to chronic pain development. We compared patients with de novo post-COVID-19 pain with individuals with chronic pain due to knee osteoarthritis (OA) and investigated whether opioid receptor Mu 1 () polymorphisms (rs1799971; rs1799972) were associated with de novo pain.
Seventy-one post-COVID-19 pain patients, 113 patients with knee OA, and 157 controls without chronic pain were evaluated using physical examinations, pain assessments, and standardized questionnaires addressing quality of life, cognitive function, emotional status, and sociodemographic data. polymorphisms were genotyped using the TaqMan Real-Time qPCR. Pain characteristics were compared using the test, while Fisher exact test and logistic regression were applied to assess risk factors and calculated odds ratios.
Although chronic pain intensity was similar between the 2 cohorts, de novo post-COVID-19 pain patients reported higher opioid intake, increased pain sensitivity, and more catastrophic thinking. By contrast, patients with knee OA provided clearer descriptions of their pain and exhibited higher levels of depression and cognitive impairment. Musculoskeletal disorders and lower pain pressure threshold were significantly associated with post-COVID-19 pain development. Although the frequencies of -mutated alleles varied between cases and controls, no significant associations were observed.
De novo post-COVID-19 pain exhibits different clinical features compared with chronic pain conditions, underscoring the need for tailored management and treatment strategies in this postpandemic scenario.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染与慢性疼痛有关，可导致残疾并影响生活质量。μ-阿片受体基因中的单核苷酸多态性会影响疼痛强度、痛觉和镇痛反应，可能促使慢性疼痛的发展。我们将新冠病毒病后新发疼痛患者与膝骨关节炎（OA）所致慢性疼痛患者进行了比较，并研究了阿片受体μ1（）多态性（rs1799971；rs1799972）是否与新发疼痛相关。
对71例新冠病毒病后疼痛患者、113例膝OA患者和157例无慢性疼痛的对照者进行了体格检查、疼痛评估，并使用标准化问卷对生活质量、认知功能、情绪状态和社会人口统计学数据进行了评估。使用TaqMan实时定量聚合酶链反应对多态性进行基因分型。采用检验比较疼痛特征，同时应用Fisher精确检验和逻辑回归评估危险因素并计算比值比。
尽管两个队列的慢性疼痛强度相似，但新冠病毒病后新发疼痛患者报告的阿片类药物摄入量更高、疼痛敏感性增加且灾难化思维更多。相比之下，膝OA患者对其疼痛的描述更清晰，且抑郁和认知障碍水平更高。肌肉骨骼疾病和较低的疼痛压力阈值与新冠病毒病后疼痛的发生显著相关。虽然突变等位基因的频率在病例组和对照组之间有所不同，但未观察到显著关联。
新冠病毒病后新发疼痛与慢性疼痛状况相比表现出不同的临床特征，这突出表明在这种疫情后情况下需要有针对性的管理和治疗策略。
